Rep. Debbie Wasserman Schultz Buys AngioDynamics, Inc. (NASDAQ:ANGO) Shares

Key Points

• Representative Debbie Wasserman Schultz purchased shares of AngioDynamics (NASDAQ:ANGO) worth between $1,001 and $15,000 on June 27th, as disclosed in a filing on July 25th.
• AngioDynamics reported a earnings per share (EPS) of ($0.03) for the latest quarter, surpassing analysts' expectations of ($0.12), with revenue up 13.0% year-over-year at $80.16 million.
• Analyst ratings for AngioDynamics have been positive, with Canaccord Genuity increasing their price target to $17.00 and HC Wainwright maintaining a buy rating with a $16.00 target.

Representative Debbie Wasserman Schultz (D-Florida) recently bought shares of AngioDynamics, Inc. NASDAQ: ANGO. In a filing disclosed on July 25th, the Representative disclosed that they had bought between $1,001 and $15,000 in AngioDynamics stock on June 27th.

Representative Debbie Wasserman Schultz also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Viasat NASDAQ: VSAT on 7/18/2025.
• Sold $1,001 - $15,000 in shares of AngioDynamics NASDAQ: ANGO on 7/16/2025.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO traded down $0.17 during trading on Friday, reaching $8.69. 86,043 shares of the company were exchanged, compared to its average volume of 653,509. The firm has a market capitalization of $353.12 million, a PE ratio of -10.52 and a beta of 0.60. The business's fifty day simple moving average is $9.79 and its 200-day simple moving average is $9.96. AngioDynamics, Inc. has a 12-month low of $5.83 and a 12-month high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The firm had revenue of $80.16 million for the quarter, compared to the consensus estimate of $74.26 million. During the same period last year, the firm earned ($0.06) earnings per share. The company's quarterly revenue was up 13.0% on a year-over-year basis. On average, sell-side analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ANGO. HC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a research note on Wednesday, July 16th. Canaccord Genuity Group increased their price objective on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. Finally, Lake Street Capital began coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They set a "buy" rating and a $24.00 price objective on the stock.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently bought and sold shares of ANGO. Charles Schwab Investment Management Inc. boosted its stake in AngioDynamics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier's stock valued at $3,014,000 after acquiring an additional 2,270 shares in the last quarter. Intech Investment Management LLC acquired a new stake in AngioDynamics in the fourth quarter valued at approximately $152,000. American Century Companies Inc. boosted its stake in AngioDynamics by 22.1% in the fourth quarter. American Century Companies Inc. now owns 67,942 shares of the medical instruments supplier's stock valued at $622,000 after acquiring an additional 12,306 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in AngioDynamics by 46.0% in the fourth quarter. JPMorgan Chase & Co. now owns 807,483 shares of the medical instruments supplier's stock valued at $7,397,000 after acquiring an additional 254,322 shares in the last quarter. Finally, Orion Portfolio Solutions LLC boosted its stake in AngioDynamics by 7.4% in the fourth quarter. Orion Portfolio Solutions LLC now owns 179,897 shares of the medical instruments supplier's stock valued at $1,648,000 after acquiring an additional 12,383 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

About Representative Wasserman Schultz

Debbie Wasserman Schultz (Democratic Party) is a member of the U.S. House, representing Florida's 25th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Wasserman Schultz (Democratic Party) is running for re-election to the U.S. House to represent Florida's 25th Congressional District. She declared candidacy for the 2026 election. Debbie Wasserman Schultz was born in Forest Hills, New York. Wasserman Schultz graduated from Half Hollow Hills High School East in 1984. She earned a B.A. and M.A. from the University of Florida in 1988 and 1990, respectively. Wasserman Schultz's career experience includes working as a staffer to former U.S. Representative Peter Deutsch.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.